Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Sep 28, 2015

Sanofi Reaches Patent Settlement on Lantus® SoloSTAR®
- Photos 1
Sep 14, 2015

Sanofi Reports Positive Top-Line Results in Second Pivotal LixiLan Phase III Study

- LixiLan met primary endpoint showing superior reduction in HbA1c vs Insulin Glargine alone -
Aug 31, 2015

Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes

- Will work together on new digital technology and tools for diabetes -
- Photos 1
Jul 30, 2015

Sanofi Delivers Solid Sales and Business EPS Growth in Q2 2015
- Photos 1
Jul 29, 2015

Sanofi Announces that First LixiLan Phase III Study Met Primary Endpoint
Jul 24, 2015

Sanofi and Regeneron Announce FDA Approval of Praluent® (alirocumab) Injection, the First PCSK9 Inhibitor in the U.S., for the Treatment of High LDL Cholesterol in Adult Patients

- Praluent available early next week to U.S. patients -
Jun 9, 2015

FDA Advisory Committee Recommends Approval of Sanofi and Regeneron's Praluent® (alirocumab) Injection for Patients with Hypercholesterolemia
- Photos 1
Jun 8, 2015

Sanofi's Lyxumia® (lixisenatide) Demonstrated Cardiovascular Safety in People with Type 2 Diabetes and High CV Risk

- ELIXA is the first event-driven cardiovascular outcomes study to provide data for a GLP-1 receptor agonist -
Jun 6, 2015

Sanofi's Lyxumia® (lixisenatide) Statistically Superior to Rapid Acting Insulin for Body Weight Change with Similar Blood Sugar Control when Both are Added to Basal Insulin
Jun 4, 2015

Sanofi Announces Study Program Evaluating Toujeo® in a Real-Life Setting

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.